Search Results

Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway

Targovax ASA announces that Innovation Norway has awarded Targovax an NOK 8.2m grant to accelerate product development activities related to the company’s TG mutant RAS vaccine program and planned clinical trials.

January 12, 2022

·

1 min read

Business

Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™

Agenus and Targovax today announce that they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines.

March 7, 2022

·

5 min read

Business

Targovax ASA appoints Ola Melin as Head of Manufacturing

Targovax ASA announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax’s Chemistry, Manufacturing, and Controls program forward.

September 30, 2021

·

2 min read

Targovax: Presentation material for today’s webcast

Targovax will at 14:00 CEST today host a live webcast presentation held by the company’s newly appointed CEO Erik Digman Wiklund .

October 25, 2021

·

1 min read

Targovax to present at upcoming scientific conferences

Targovax ASA, announces that members of its executive management team is invited to present and participate at upcoming conferences.

August 16, 2021

·

1 min read

Business

Targovax ASA: Third quarter 2021 results

Targovax ASA, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its third quarter 2021 results.

November 4, 2021

·

3 min read

Business

Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer

Targovax ASA a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer, effective as of 7 March 2022.

February 28, 2022

·

2 min read

Business

Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2021 results, Wednesday 18 August

Targovax ASA will announce its second quarter and first half 2021 results on Wednesday 18 August 2021.

August 9, 2021

·

1 min read

Targovax to present at upcoming conferences

Targovax ASA today announces that members of its executive management team are invited to present and participate in upcoming conferences. Økonomisk Ugebrev’s Life Science Investor conference Date: 20 October 2021 Presenter: Lone Ottesen (CDO) Time: 14:35 CET

October 19, 2021

·

1 min read

Targovax ASA: Two abstracts accepted at the SITC Congress

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that two abstracts has been accepted for poster presentation at the Society for Immunotherapy of Cancer Annual Meeting.

October 6, 2021

·

1 min read